Bristol Myers Squibb and Sarah Cannon Research Institute Expand Strategic Collaboration to Accelerate Cancer Clinical Trials
核心洞察
Bristol Myers Squibb (搜索) and Sarah Cannon Research Institute (搜索) announced an expanded strategic collaboration to accelerate innovative cancer therapy development and increase clinical trial access across the U.S.
The collaboration achieved a 45% reduction in study startup timelines across eight Bristol Myers Squibb (搜索) clinical trials, significantly outperforming non-SCRI sites.
SCRI's Accelero model streamlines operations across more than 200 locations with over 1,300 physicians, bringing cutting-edge research directly to patients in community settings.
Bristol Myers Squibb (搜索) and Sarah Cannon Research Institute (搜索) (SCRI) announced an expanded strategic collaboration aimed at accelerating the development of innovative cancer therapies and increasing access to clinical trials for patients across the United States. The partnership leverages SCRI's next-generation clinical trial delivery model to bring cutting-edge research directly to patients in their communities.
Accelerated Trial Execution Through Operational Innovation
Central to the collaboration is SCRI's Accelero, a next-generation clinical trial delivery model that streamlines operations and accelerates trial execution across SCRI's expansive network of more than 200 locations. The partnership aligns Bristol Myers Squibb (搜索)'s pioneering oncology pipeline with SCRI's research infrastructure and expertise to deliver research where patients live and receive care.
In the early phase of the collaboration, SCRI achieved a 45% reduction in study startup timelines across eight Bristol Myers Squibb (搜索) clinical trials—significantly outperforming timelines observed at non-SCRI sites. These capabilities are being scaled across SCRI's research network to transform clinical trial delivery and ensure more patients can access the latest cancer treatments and innovations.
Expanding Community-Based Research Access
The collaboration expands access to Bristol Myers Squibb (搜索)'s innovative therapies by embedding clinical trials in community settings. SCRI's network engages more than 1,300 physicians in research across over 20 states, enabling broader participation in clinical trials and reaching patients who might otherwise lack access to experimental treatments.
"Together, SCRI and Bristol Myers Squibb (搜索) are translating innovative science into clinical trials and accelerating patient enrollment through SCRI's Accelero model that prioritizes speed, quality, and access, and ultimately brings promising therapies to patients faster and closer to home," said Dee Anna Smith, Chief Executive Officer of SCRI.
Commitment to Health Equity and Inclusion
The partnership emphasizes improving access to clinical research for medically underserved populations through data-driven strategies. Bristol Myers Squibb (搜索) views the collaboration as essential to advancing health equity across the oncology landscape.
"At Bristol Myers Squibb, we recognize that accelerating clinical trial enrollment requires not only scientific innovation but also operational innovation. This includes a deep commitment to equity and inclusion, while we look to accelerate overall patient enrollment," said Mokash Sharma, Senior Vice President, Global Development Operations at Bristol Myers Squibb (搜索). "Improving access to clinical research isn't just about science—it's about trust, and meeting people where they are."
Research Network Impact
SCRI has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that led to the majority of new cancer therapies approved by the FDA in the past decade. The organization's community-based approach brings clinical trials to patients across more than 20 states, addressing geographic barriers that often prevent participation in cancer research.
The expanded collaboration reinforces both organizations' shared commitment to transforming clinical trial delivery and ensuring that innovative cancer treatments reach more patients in their local communities.